(Q77769295)

English

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

scientific article published on 01 May 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Jacques P. Brown

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

author name string

P D Miller

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

E S Siris

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

M S Hoseyni

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

D W Axelrod

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

P J Bekker

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 May 1999

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

American Journal of Medicine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

106

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

513-520

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Treatment of Paget's disease of bone with single dose intravenous pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Intravenous aminobisphosphonate in Paget's disease: clinical, biochemical, histomorphometric and radiological responses

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Paget's disease of bone treated with a five day course of oral tiludronate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Long-term therapy of Paget's disease of bone with EHDP

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Use of etidronate (EHDP) in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

The management of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Diphosphonate Therapy of Paget's Disease of Bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Efficacy of the bisphosphonate APD in the control of Paget's bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Clinical and biological effects of low doses of (3 amino-1 hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Pamidronate: an unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

"Pill esophagitis"--the case of alendronate

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Effects of two oral doses of alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

APD in Paget's disease of bone. Role of the mononuclear phagocyte system?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

The effects of intravenous alendronate in Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Calcitonin Resistance: Clinical and Immunologic Studies in Subjects with Paget's Disease of Bone Treated with Porcine and Salmon Calcitonins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

An evaluation of antibodies and clinical resistance to salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

Treating Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2900062-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-9343(99)00062-5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10335722%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q77769295&oldid=2088452377"